2-[(4-pyridyl)methyl]amino-N-[3-methoxy-5-(trifluoromethyl)phenyl]benzamide

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 2-[(4-pyridyl)methyl]amino-N-[3-methoxy-5-(trifluoromethyl)phenyl]benzamide
• 英文别名: 2-[(pyridin-4-yl)methyl]amino-N-[3-methoxy-5-(trifluoromethyl)phenyl]benzamide；N-[3-methoxy-5-(trifluoromethyl)phenyl]-2-(pyridin-4-ylmethylamino)benzamide
• 化学式: C₂₁H₁₈F₃N₃O₂
• 分子量: 401.388
• InChiKey: UQKMNJCWRXFQEZ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.6
• 重原子数：
  29
• 可旋转键数：
  6
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.14
• 拓扑面积：
  63.2
• 氢给体数：
  2
• 氢受体数：
  7

文献信息

• N-aryl(thio)anthranilic acid amide derivatives, their preparation and their use as VEGF receptor tyrosine kinase inhibitors
  申请人：——

  公开号：US20020019414A1

  公开（公告）日：2002-02-14

  1 Described are compounds of formula (I), wherein W is O or S; X is NR 8 ; Y is CR 9 R 10 -(CH 2 )n wherein R 9 and R 10 are independently of each other hydrogen or lower alkyl, and n is an integer of from and including 0 to and including 3; or Y is SO 2 ; R 1 is aryl; R 2 is a mono- or bicyclic heteroaryl group comprising one or more ring nitrogen atoms with the exception that R 2 cannot represent 2-phthalimidyl, and in case of Y═SO 2 cannot represent 2,1,3-benzothiadiazol-4-yl; any of R 3 , R 4 , R 5 and R 6 , independently of the other, is H or a substituent other than hydrogen; and R 7 and R 8 , independently of each other, are H or lower alkyl; or a N-oxide or a pharmaceutically acceptable salt thereof for the preparation of a pharmaceutical product for the treatment of a neoplastic disease which responds to an inhibition of the VEGF receptor tyrosine kinase activity. The compounds of formula (I) can be used for the treatment e.g. of a neoplastic disease, such as a tumor disease, of retinopathy and age-related macular degeneration.

  描述的是化合物的结构式（I），其中W是O或S；X是NR8；Y是CR9R10-(CH2)n，其中R9和R10彼此独立地是氢或较低的烷基，n是从0到3的整数；或Y是SO2；R1是芳基；R2是一个含有一个或多个环氮原子的单环或双环杂环基团，但R2不能代表2-邻苯二甲酰胺，并且在Y为SO2的情况下不能代表2,1,3-苯并噻二唑-4-基；R3、R4、R5和R6中的任何一个，独立于其他，是H或除氢之外的取代基；R7和R8，彼此独立地是H或较低的烷基；或其N-氧化物或药用可接受的盐，用于制备用于治疗对VEGF受体酪氨酸激酶活性抑制产生反应的恶性疾病的药物产品。结构式（I）的化合物可用于治疗恶性疾病，如肿瘤疾病，视网膜病和老年性黄斑变性等。
• Immunosuppressant Compounds and Compositions
  申请人：Pan Shifeng

  公开号：US20070203100A1

  公开（公告）日：2007-08-30

  The present invention relates to immunosuppressant, process for their production, their uses and pharmaceutical compositions containing them. The invention provides a novel class of compounds useful in the treatment or prevention of diseases or disorders mediated by lymphocyte interactions, particularly diseases associated with EDG receptor mediated signal transduction.

  本发明涉及免疫抑制剂，其生产过程，它们的用途以及含有它们的药物组合物。本发明提供了一类新型化合物，可用于治疗或预防由淋巴细胞相互作用介导的疾病或紊乱，特别是与EDG受体介导的信号转导相关的疾病。
• [EN] IMMUNOSUPPRESSANT COMPOUNDS AND COMPOSITIONS<br/>[FR] COMPOSES ET COMPOSITIONS D'IMMUNOSUPPRESSEURS
  申请人：IRM LLC

  公开号：WO2005082841A1

  公开（公告）日：2005-09-09

  The present invention relates to immunosuppressants, processes for their production, their uses and pharmaceutical compositions containing them. The invention provides a novel class of compounds useful in the treatment or prevention of diseases or disorders mediated by lymphocyte interactions, particularly diseases associated with EDG receptor mediated signal transduction.

  本发明涉及免疫抑制剂，其生产过程，其用途以及含有它们的药物组合物。本发明提供了一类新型化合物，可用于治疗或预防由淋巴细胞相互作用介导的疾病或紊乱，特别是与EDG受体介导的信号传导相关的疾病。
• [EN] NEW SALTS<br/>[FR] NOUVEAUX SELS
  申请人：NOVARTIS AG

  公开号：WO2010080455A1

  公开（公告）日：2010-07-15

  This invention relates to a hydrochloride, malafe, oxalate and tartrate salt forms of 1-(4- 1-[(E)-4-cyclohexyl-3-trifluoromethyl-benzyloxyimino]-ethyl}-2-ethyl-benzyI)-azetidine- 3-carboxylic acid (Compound I), to pharmaceutical compositions comprising this salt, to processes for forming this salt and to its use in medical treatment. In addition, the present invention also relates to new polymorphic forms of each of these salts, as well as to pharmaceutical compositions comprising these polymorphic forms, to processes for obtaining them, and their use in medical treatment.

  本发明涉及1-(4-1-[(E)-4-环己基-3-三氟甲基苄氧基亚胺基]-乙基}-2-乙基苯基)-氮杂环己烷-3-羧酸（化合物I）的盐形式，包括盐酸盐、马来酸盐、草酸盐和酒石酸盐，以及包含这些盐的制药组合物，制备这些盐的方法以及其在医疗治疗中的应用。此外，本发明还涉及每种这些盐的新的多晶形式，以及包含这些多晶形式的制药组合物，制备它们的方法以及它们在医疗治疗中的应用。
• [EN] NEW POLYMORPHIC FORM OF 1- (4- { L- [ (E) -4-CYCLOHEXYL--3-TRIFLUOROMETHYL-BENZYLOXYIMINO] -ETHYL) -2-ETHYL-BENZY L) -AZETIDINE-3-CARBOXYLIC<br/>[FR] NOUVELLE FORME POLYMORPHE DE 1-(4-{L-[(E)-4-CYCLOHEXYL-3-TRIFLUOROMÉTHYL-BENZYLOXYIMINO]-ÉTHYL}-2-ÉTHYL-BENZYL)-AZÉTIDINE-S-CARBOXYLIQUE
  申请人：NOVARTIS AG

  公开号：WO2010071794A1

  公开（公告）日：2010-06-24

  This invention relates to a novel crystalline form (Form A) of 1-(4-1-[(E)-4-cyclohexyl-3-trifluoromethyl-benzyloxyimino]-ethyl}-2-ethyl-benzyl)-azetidine-3-carboxylic acid (Compound I), to pharmaceutical compositions comprising this crystalline form, to processes for forming it and to its use in medical treatment.

  本发明涉及一种新型晶体形态（A型）的1-（4- 1- [(E)-4-环己基-3-三氟甲基苄氧基亚胺基]-乙基}-2-乙基苯甲基）-氮杂环丙氨酸（化合物I），以及包含该晶体形态的制药组合物，制备该晶体形态的方法以及其在医学治疗中的应用。